Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,311 ILa | -4.10% | -1.87% | -11.30% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 293.9 | 228 | 305.9 | 265.7 | 175.7 | 168.7 |
Enterprise Value (EV) 1 | 346.5 | 342 | 435.3 | 412.9 | 321.1 | 335.2 |
P/E ratio | 41.7 x | 57.2 x | 28.3 x | 40.1 x | -85.5 x | -24.2 x |
Yield | - | - | - | 3.73% | - | - |
Capitalization / Revenue | 1.41 x | 1.16 x | 1.15 x | 1.01 x | 0.6 x | 0.52 x |
EV / Revenue | 1.67 x | 1.74 x | 1.64 x | 1.56 x | 1.1 x | 1.04 x |
EV / EBITDA | 13.7 x | 14 x | 12.4 x | 13.7 x | 9.28 x | 12.9 x |
EV / FCF | -217 x | -92.6 x | -40.7 x | -2,008 x | 9.66 x | 33.2 x |
FCF Yield | -0.46% | -1.08% | -2.45% | -0.05% | 10.4% | 3.01% |
Price to Book | 1.94 x | 1.47 x | 1.85 x | 1.54 x | 1.08 x | 1.08 x |
Nbr of stocks (in thousands) | 11,415 | 11,415 | 11,415 | 11,415 | 11,415 | 11,415 |
Reference price 2 | 25.75 | 19.97 | 26.80 | 23.28 | 15.39 | 14.78 |
Announcement Date | 28/03/19 | 31/03/20 | 22/03/21 | 30/03/22 | 29/03/23 | 26/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 207.8 | 196.5 | 265.5 | 264 | 292.4 | 321.7 |
EBITDA 1 | 25.38 | 24.45 | 35.17 | 30.09 | 34.61 | 26.03 |
EBIT 1 | 14.63 | 12.6 | 20.89 | 12.91 | 13.25 | 2.906 |
Operating Margin | 7.04% | 6.41% | 7.87% | 4.89% | 4.53% | 0.9% |
Earnings before Tax (EBT) 1 | 9.918 | 4.543 | 14.16 | 7.71 | 0.357 | -7.05 |
Net income 1 | 7.005 | 3.987 | 10.8 | 6.624 | -2.041 | -6.91 |
Net margin | 3.37% | 2.03% | 4.07% | 2.51% | -0.7% | -2.15% |
EPS 2 | 0.6181 | 0.3493 | 0.9459 | 0.5800 | -0.1800 | -0.6100 |
Free Cash Flow 1 | -1.6 | -3.694 | -10.68 | -0.2056 | 33.25 | 10.09 |
FCF margin | -0.77% | -1.88% | -4.02% | -0.08% | 11.37% | 3.14% |
FCF Conversion (EBITDA) | - | - | - | - | 96.06% | 38.78% |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | 0.8678 | - | - |
Announcement Date | 28/03/19 | 31/03/20 | 22/03/21 | 30/03/22 | 29/03/23 | 26/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 52.6 | 114 | 129 | 147 | 145 | 166 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.071 x | 4.665 x | 3.68 x | 4.891 x | 4.201 x | 6.395 x |
Free Cash Flow 1 | -1.6 | -3.69 | -10.7 | -0.21 | 33.2 | 10.1 |
ROE (net income / shareholders' equity) | 4.64% | 1.8% | 6.73% | 3.91% | -1.22% | -4.35% |
ROA (Net income/ Total Assets) | 3.07% | 2.36% | 3.32% | 1.88% | 1.87% | 0.39% |
Assets 1 | 228.1 | 168.9 | 325.3 | 351.6 | -109.1 | -1,775 |
Book Value Per Share 2 | 13.30 | 13.60 | 14.50 | 15.20 | 14.20 | 13.60 |
Cash Flow per Share 2 | 2.780 | 2.240 | 3.230 | 1.630 | 1.770 | 1.690 |
Capex 1 | 15.2 | 43.1 | 18.6 | 13.5 | 6.93 | 11.5 |
Capex / Sales | 7.3% | 21.94% | 7.02% | 5.11% | 2.37% | 3.57% |
Announcement Date | 28/03/19 | 31/03/20 | 22/03/21 | 30/03/22 | 29/03/23 | 26/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-11.30% | 39.24M | |
+16.30% | 71.39B | |
+1.83% | 25.1B | |
-1.22% | 8.59B | |
+7.95% | 8.19B | |
-20.48% | 7.91B | |
+15.26% | 4.31B | |
-1.24% | 3.93B | |
-3.02% | 3.86B | |
+21.10% | 3.64B |
- Stock Market
- Equities
- REKA Stock
- Financials Rekah Pharmaceutical Industry Ltd.